» Articles » PMID: 35306658

New-onset Refractory Status Epilepticus As an Early Manifestation of Multisystem Inflammatory Syndrome in Adults After COVID-19

Overview
Journal Epilepsia
Specialty Neurology
Date 2022 Mar 20
PMID 35306658
Authors
Affiliations
Soon will be listed here.
Abstract

Multisystem inflammatory syndrome in adults (MIS-A) is a rare hyperinflammatory complication with multi-organ involvement that manifests a few weeks after recovering from a typically mild coronavirus disease 2019 (COVID-19) infection. Although encephalopathy and seizures can occur in the acute phase of COVID-19, the nervous system is infrequently involved in patients with MIS-A. Herein, we describe the case of a young woman who presented with new-onset refractory status epilepticus (NORSE) following a mild COVID-19 infection associated with symptoms, signs, and laboratory findings that satisfy the updated Centers for Disease Control and Prevention (CDC) definition of MIS-A. Magnetic resonance imaging of the brain revealed symmetric T2-signal increase involving both orbitofrontal lobes, insulae, and hippocampi. One of the notable findings in our patient was the quick response and significant clinical recovery that occurred following initiation of treatment with intravenous methylprednisolone and intravenous immunoglobulin. Our case expands the clinical spectrum of MIS-A and documents the occurrence of NORSE as one of its early clinical manifestations. A routine comprehensive clinical and laboratory assessment is needed to screen for this underdiagnosed condition, especially in patients with post-COVID-19 inflammatory complications.

Citing Articles

Multisystem Inflammatory Syndrome of the Adults (MIS-A) - The undercover threat for young adults. A systematic review and meta-analysis of medical cases.

Michailides C, Papantoniou K, Paraskevas T, Lagadinou M, Marangos M, Kavvousanos M Infez Med. 2024; 32(3):272-279.

PMID: 39282538 PMC: 11392540. DOI: 10.53854/liim-3203-2.


Seizure burden and neuropsychological outcomes of new-onset refractory status epilepticus: Systematic review.

Taraschenko O, Pavuluri S, Schmidt C, Pulluru Y, Gupta N Front Neurol. 2023; 14:1095061.

PMID: 36761344 PMC: 9902772. DOI: 10.3389/fneur.2023.1095061.


New-onset refractory status epilepticus as an early manifestation of multisystem inflammatory syndrome in adults after COVID-19.

Nawfal O, Toufaili H, Dib G, Dirani M, Beydoun A Epilepsia. 2022; 63(5):e51-e56.

PMID: 35306658 PMC: 9111422. DOI: 10.1111/epi.17231.

References
1.
Feldstein L, Rose E, Horwitz S, Collins J, Newhams M, Son M . Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020; 383(4):334-346. PMC: 7346765. DOI: 10.1056/NEJMoa2021680. View

2.
Bastug A, Aslaner H, Bilir Y, Kemirtlek N, Gursoy F, Bastug S . Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Rheumatol Int. 2021; 41(5):993-1008. PMC: 7978449. DOI: 10.1007/s00296-021-04843-1. View

3.
Yanagida A, Kanazawa N, Kaneko J, Kaneko A, Iwase R, Suga H . Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Neurol Neuroimmunol Neuroinflamm. 2020; 7(5). PMC: 7413708. DOI: 10.1212/NXI.0000000000000849. View

4.
Suchdev K, Kupsky W, Mittal S, Shah A . Histopathology of new-onset refractory status epilepticus (NORSE) in adults. Seizure. 2021; 93:95-101. DOI: 10.1016/j.seizure.2021.09.018. View

5.
Pellinen J, Carroll E, Friedman D, Boffa M, Dugan P, Friedman D . Continuous EEG findings in patients with COVID-19 infection admitted to a New York academic hospital system. Epilepsia. 2020; 61(10):2097-2105. DOI: 10.1111/epi.16667. View